Company Name: Pharming Group NV ISIN: NL0010391025   Reason for the research: Q3/24 results Recommendation: Buy from: 29.10.2024 Target price: €1.70 Target price on sight of: 12 months Last rating change: - Analyst: Simon Scholes First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010 [ … ]

First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and increased the price target from EUR 1.50 to EUR 1.60. Abstract: Q2/23 saw the expected sequential recovery in Ruconest sales (+20.1%) following temporary reimbursement problems in Q1/23. Ruc [ … ]

First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and decreased the price target from EUR 1.80 to EUR 1.50. Abstract: Pharming's orphan drug, Joenja, for the treatment of the rare disease, activated PI3K delta syndrome (APDS), was approved in t [ … ]

First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and decreased the price target from EUR 1.80 to EUR 1.50. Abstract: Pharming's orphan drug, Joenja, for the treatment of the rare disease, activated PI3K delta syndrome (APDS), was approved in t [ … ]

First Berlin Equity Research hat ein Research Update zu Pharming Group NV (ISIN: NL0010391025) veröffentlicht. Analyst Simon Scholes bestätigt seine BUY-Empfehlung und senkt das Kursziel von EUR 2,10 auf EUR 1,80. Zusammenfassung: Die Q2/20-Ergebnisse von Pharming zeigten einen Umsatzrückgang von 8% gegenüber dem Vorjahr auf  [ … ]